Thomas P Miller

  • 19247 Citations
  • 57 h-Index
1978 …2016

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J. & Salmon, S. E., Jan 1 1991, In : Journal of Clinical Oncology. 9, 1, p. 17-24 8 p.

Research output: Contribution to journalArticle

367 Scopus citations

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Barr, P. M., Miller, T. P., Friedberg, J. W., Peterson, D. R., Baran, A. M., Herr, M., Spier, C. M., Cui, H., Roe, D. J., Persky, D. O., Casulo, C., Littleton, J., Schwartz, M., Puvvada, S., Landowski, T. H., Rimsza, L. M., Dorr, R. T., Fisher, R. I., Bernstein, S. H. & Briehl, M. M., Aug 21 2014, In : Blood. 124, 8, p. 1259-1265 7 p.

Research output: Contribution to journalArticle

15 Scopus citations

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350

Mahadevan, D., Unger, J. M., Spier, C. M., Persky, D. O., Young, F., Leblanc, M., Fisher, R. I. & Miller, T. P., Jan 15 2013, In : Cancer. 119, 2, p. 371-379 9 p.

Research output: Contribution to journalArticle

74 Scopus citations

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

Czuczman, M. S., Thall, A., Witzig, T. E., Vose, J. M., Younes, A., Emmanouilides, C., Miller, T. P., Moore, J. O., Leonard, J. P., Gordon, L. I., Sweetenham, J., Alkuzweny, B., Finucane, D. M. & Leigh, B. R., Dec 1 2005, In : Journal of Clinical Oncology. 23, 19, p. 4390-4398 9 p.

Research output: Contribution to journalArticle

140 Scopus citations

Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest oncology group trial

Taylor, C. W., LeBlanc, M., Fisher, R. I., Moore, D. F., Roach, R. W., Elias, L. & Miller, T. P., Dec 19 2000, In : Anti-cancer drugs. 11, 9, p. 695-700 6 p.

Research output: Contribution to journalArticle

18 Scopus citations

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

Atiba, J. O., Green, S. J., Hynes, H. E., Osborne, C. K., Miller, T. P. & Davidner, M., Jun 1 1994, In : Investigational New Drugs. 12, 2, p. 129-132 4 p.

Research output: Contribution to journalArticle

5 Scopus citations

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: SWOG S0016

Press, O. W., Unger, J. M., Rimsza, L. M., Friedberg, J. W., LeBlanc, M., Czuczman, M. S., Kaminski, M., Braziel, R. M., Spier, C., Gopal, A. K., Maloney, D. G., Cheson, B. D., Dakhil, S. R., Miller, T. P. & Fisher, R. I., Jan 20 2013, In : Journal of Clinical Oncology. 31, 3, p. 314-320 7 p.

Research output: Contribution to journalArticle

110 Scopus citations

Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer: A southwest oncology group study

Von Hoff, D. D., Green, S., Alberts, D. S., Stock-Novack, D. L., Surwit, E. A., Miller, T. P. & Stephens, R. L., Jan 1 1991, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 14, 3, p. 193-194 2 p.

Research output: Contribution to journalArticle

7 Scopus citations

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014

Persky, D. O., Unger, J. M., Spier, C. M., Stea, B., LeBlanc, M., McCarty, M. J., Rimsza, L. M., Fisher, R. I. & Miller, T. P., Sep 15 2008, In : Journal of Clinical Oncology. 26, 14, p. 2258-2263 6 p.

Research output: Contribution to journalArticle

174 Scopus citations
3 Scopus citations

Phase II trial of bisantrene in non-small cell lung cancer

Miller, T. P., Ahmann, F. R., Mackel, C., Greenberg, B. R. & Alberts, D. S., Dec 1 1985, In : Investigational New Drugs. 3, 4, p. 393-395 3 p.

Research output: Contribution to journalArticle

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Miller, T. P., Jones, S. E., Alberts, D. S. & Mackel, C., Mar 1 1984, In : Investigational New Drugs. 2, 1, p. 75-77 3 p.

Research output: Contribution to journalArticle

2 Scopus citations

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911

Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M. & Fisher, R. I., Sep 1 2006, In : Journal of Clinical Oncology. 24, 25, p. 4143-4149 7 p.

Research output: Contribution to journalArticle

198 Scopus citations

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Braich, T. A., Salmon, S. E., Robertone, A., Alberts, D. S., Jones, S. E., Miller, T. P. & Garewal, H. S., Sep 1 1986, In : Investigational New Drugs. 4, 3, p. 269-274 6 p.

Research output: Contribution to journalArticle

6 Scopus citations

Phase II trial of menogaril in non-Hodgkin's lymphomas: A southwest oncology group trial

Moore, D. F., Brown, T. D., LeBlanc, M., Dahlberg, S., Miller, T. P., McClure, S. & Fisher, R. I., Dec 22 1999, In : Investigational New Drugs. 17, 2, p. 169-172 4 p.

Research output: Contribution to journalArticle

2 Scopus citations

Phase II trial of vindesine in breast cancer, lymphoma and other tumors: Future directions

Miller, T. P., Jones, S. E., Chester, A. B. & Dorr, R. T., Sep 1980, In : Cancer Treatment Reviews. 7, SUPPL. 1, p. 81-86 6 p.

Research output: Contribution to journalArticle

9 Scopus citations

Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

Miller, T. P., Jones, S. E. & Chester, A., Dec 1 1980, In : Cancer Treatment Reports. 64, 8-9, p. 1001-1003 3 p.

Research output: Contribution to journalArticle

8 Scopus citations

Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T. P., Burger, J. A., Kelly, K. R., Mahadevan, D., Ma, S., Li, Y., Pierce, D. W., Barnett, E., Marine, J., Miranda, M., Azaryan, A., Yu, X. & 3 others, Nava-Parada, P., Mei, J. & Kipps, T. J., Jan 1 2016, In : Haematologica. 101, 7, p. e295-e298

Research output: Contribution to journalLetter

26 Scopus citations

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial

Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W. S., Hong, F., Tan, K. L., Gascoyne, R. D., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Stiff, P., Cheson, B. D., Advani, R., Miller, T. P., Kahl, B. S., Horning, S. J. & Ambinder, R. F., May 2 2013, In : Blood. 121, 18, p. 3547-3553 7 p.

Research output: Contribution to journalArticle

77 Scopus citations

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Muller-Hermelink, H. K., Ott, G., Chan, W. C., Greiner, T. C., Weisenburger, D. D., Vose, J., Armitage, J. O., Gascoyne, R. D., Connors, J. M., Campo, E., Montserrat, E., Bosch, F. & 10 others, Smeland, E. B., Kvaloy, S., Holte, H., Delabie, J., Fisher, R. I., Grogan, T. M., Miller, T. P., Wilson, W. H., Jaffe, E. S. & Staudt, L. M., Jun 1 2007, In : Blood. 109, 11, p. 4599-4606 8 p.

Research output: Contribution to journalArticle

160 Scopus citations

Post-transplantation T cell lymphoblastic lymphoma

Lippman, S. M., Grogan, T. M., Carry, P., Ogden, D. A. & Miller, T. P., Apr 1987, In : The American journal of medicine. 82, 4, p. 814-816 3 p.

Research output: Contribution to journalArticle

45 Scopus citations

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by p-glycoprotein staining

Salmon, S. E., Grogan, T. M., Miller, T., Scheper, R. & Dalton, W. S., May 3 1989, In : Journal of the National Cancer Institute. 81, 9, p. 696-701 6 p.

Research output: Contribution to journalArticle

179 Scopus citations

Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-a, b, c) phenotype

Rybski, J. A., Spier, C. M., Miller, T. P., Lippman, S. M., Mcgee, D. L. & Grogan, T. M., Jan 1 1991, In : Leukemia and Lymphoma. 6, 1, p. 31-38 8 p.

Research output: Contribution to journalArticle

7 Scopus citations

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells

Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., Miller, T. P., LeBlanc, M., Greiner, T. C., Weisenburger, D. D., Lynch, J. C., Vose, J., Armitage, J. O., Smeland, E. B., Kvaloy, S., Holte, H. & 20 others, Delabie, J., Connors, J. M., Lansdorp, P. M., Ouyang, Q., Lister, T. A., Davies, A. J., Norton, A. J., Muller-Hermelink, H. K., Ott, G., Campo, E., Montserrat, E., Wilson, W. H., Jaffe, E. S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. & Staudt, L. M., Nov 18 2004, In : New England Journal of Medicine. 351, 21, p. 2159-2169 11 p.

Research output: Contribution to journalArticle

1029 Scopus citations

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial

Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel, R. M., Banks, P. M., Foucar, K., Kjeldsberg, C. R., Levy, N., Nathwani, B. N., Schnitzer, B., Tubbs, R. R., Gaynor, E. R. & Fisher, R. I., Mar 15 1994, In : Blood. 83, 6, p. 1460-1466 7 p.

Research output: Contribution to journalArticle

220 Scopus citations

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder

Swinnen, L. J., Leblanc, M., Grogan, T. M., Gordon, L. I., Stiff, P. J., Miller, A. M., Kasamon, Y., Miller, T. P. & Fisher, R. I., Jul 27 2008, In : Transplantation. 86, 2, p. 215-222 8 p.

Research output: Contribution to journalArticle

71 Scopus citations

Pseudonodular T cell lymphoblastic lymphoma

Schwarte, J. E., Grogan, T. M., Hicks, M. J., Weinrach, R. S. & Miller, T. P., Nov 1984, In : The American journal of medicine. 77, 5, p. 947-949 3 p.

Research output: Contribution to journalArticle

5 Scopus citations

Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma

Roberts, R. A., Sabalos, C. M., LeBlanc, M. L., Martel, R. R., Frutiger, Y. M., Unger, J. M., Botros, I. W., Rounseville, M. P., Seligmann, B. E., Miller, T. P., Grogan, T. M. & Rimsza, L. M., Oct 1 2007, In : Laboratory Investigation. 87, 10, p. 979-997 19 p.

Research output: Contribution to journalArticle

35 Scopus citations

Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study

Nabhan, C., Byrtek, M., Taylor, M. D., Friedberg, J. W., Cerhan, J. R., Hainsworth, J. D., Miller, T. P., Hirata, J., Link, B. K. & Flowers, C. R., Oct 1 2012, In : Cancer. 118, 19, p. 4842-4850 9 p.

Research output: Contribution to journalArticle

22 Scopus citations

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

Fox, K. A., Lippman, S. M., Cassady, J. R., Heusinkveld, R. S. & Miller, T. P., Jan 1 1987, In : Journal of Clinical Oncology. 5, 1, p. 38-45 8 p.

Research output: Contribution to journalArticle

53 Scopus citations

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

Leigh, B. R., Fox, K. A., Mack, C. F., Baier, M., Miller, T. P. & Cassady, J. R., Nov 15 1993, In : International Journal of Radiation Oncology, Biology, Physics. 27, 4, p. 855-862 8 p.

Research output: Contribution to journalArticle

35 Scopus citations

Radiotherapy is NOT essential to cure diffuse large B-cell non-Hodgkin lymphoma

Puvvada, S. & Miller, T., May 20 2013, In : ONCOLOGY (United States). 27, 5

Research output: Contribution to journalComment/debate

Rationale for the use of chemotherapy in non-small cell lung cancer

Miller, T. P., Jan 1 1990, In : Seminars in Oncology. 17, 4 SUPPL. 7, p. 11-13 3 p.

Research output: Contribution to journalArticle

8 Scopus citations

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433

Friedberg, J. W., Unger, J. M., Burack, W. R., Gopal, A. K., Raju, R. N., Nademanee, A. P., Kaminski, M. S., Li, H., Press, O. W., Miller, T. P. & Fisher, R. I., Aug 2014, In : British Journal of Haematology. 166, 3, p. 382-389 8 p.

Research output: Contribution to journalArticle

18 Scopus citations

Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: The end of the story?" Haematologica. 2012;97(11): e45

Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M., Maloney, D. G., Press, O. W., Miller, T. P. & Rimsza, L. M., Nov 1 2012, In : Haematologica. 97, 11, p. e46

Research output: Contribution to journalLetter

Reply to M.C. Chamberlain

Bernstein, S. H., Unger, J. M., LeBlanc, M., Friedberg, J., Miller, T. P. & Fisher, R. I., Jul 20 2009, In : Journal of Clinical Oncology. 27, 21, p. e27-e28

Research output: Contribution to journalEditorial

1 Scopus citations

Salvage therapy of advanced hodgkin's disease. Critical appraisal of curative potential

Buzaid, A. C., Lippman, S. M. & Miller, T. P., Sep 1987, In : The American journal of medicine. 83, 3, p. 523-532 10 p.

Research output: Contribution to journalArticle

47 Scopus citations
1 Scopus citations

Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas

Fisher, R. I., Miller, T. P., Dana, B. W., Jones, S. E., Dahlberg, S. & Coltman, C. A., Apr 1 1987, In : Seminars in Hematology. 24, 2 SUPPL. 1, p. 21-25 5 p.

Research output: Contribution to journalArticle

51 Scopus citations

Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.

Miller, T. P., Dana, B. W., Weick, J. K., Jones, S. E., Coltman, C. A., Dahlberg, S. & Fisher, R. I., Apr 1988, In : Seminars in hematology. 25, 2 Suppl 2, p. 17-22 6 p.

Research output: Contribution to journalArticle

36 Scopus citations

Stromal gene signatures in large-B-cell lymphomas

Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D. D., Greiner, T. C., Armitage, J. O., Kyle, A., May, L., Gascoyne, R. D., Connors, J. M. & 30 others, Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E. B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R. M., Miller, T. P., Rimsza, L. M., Cook, J. R., Pohlman, B., Sweetenham, J., Tubbs, R. R., Fisher, R. I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H. K., Wrench, D., Lister, T. A., Jaffe, E. S., Wilson, W. H., Chan, W. C. & Staudt, L. M., Nov 27 2008, In : New England Journal of Medicine. 359, 22, p. 2313-2323 11 p.

Research output: Contribution to journalArticle

1067 Scopus citations

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration

Pennock, G. D., Dalton, W. S., Roeske, W. R., Appleton, C. P., Mosley, K., Plezia, P., Miller, T. P. & Salmon, S. E., Jan 16 1991, In : Journal of the National Cancer Institute. 83, 2, p. 105-110 6 p.

Research output: Contribution to journalArticle

160 Scopus citations

The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma

Spier, C. M., Grogan, T. M., Lippman, S. M., Slymen, D. J., Rybski, J. A. & Miller, T. P., Jan 1 1988, In : American Journal of Pathology. 133, 1, p. 118-126 9 p.

Research output: Contribution to journalArticle

38 Scopus citations

The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

Braziel, R. M., Arber, D. A., Slovak, M. L., Gulley, M. L., Spier, C., Kjeldsberg, C., Unger, J., Miller, T. P., Tubbs, R., Leith, C., Fisher, R. I. & Grogan, T. M., Jun 15 2001, In : Blood. 97, 12, p. 3713-3720 8 p.

Research output: Contribution to journalArticle

89 Scopus citations

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496

Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Gospodarowicz, M., Cheson, B. D., Stiff, P. J., Advani, R., Miller, T. P., Hoppe, R. T., Kahl, B. S. & Horning, S. J., Apr 1 2013, In : British Journal of Haematology. 161, 1, p. 76-86 11 p.

Research output: Contribution to journalArticle

71 Scopus citations

The limits of limited stage lymphoma

Miller, T. P., Dec 1 2004, In : Journal of Clinical Oncology. 22, 15, p. 2982-2984 3 p.

Research output: Contribution to journalEditorial

40 Scopus citations

The phenomenon of multidrug resistance in non-Hodgkin's lymphoma.

Miller, T. P., Chase, E. M., Dalton, W. S. & Grogan, T. M., 1996, In : Cancer treatment and research. 85, p. 107-117 11 p.

Research output: Contribution to journalReview article

6 Scopus citations

The presence of bcl-l and bci-2 gene rearrangements in diffuse small cleaved-cell lymphoma

Leith, C. P., Willman, C. L., Spier, C. M., Miller, T. P. & Grogan, T. M., Sep 1994, In : Diagnostic Molecular Pathology. 3, 3, p. 178-183 6 p.

Research output: Contribution to journalArticle

2 Scopus citations

The prognostic significance of the immunotype in diffuse large-cell lymphoma: A comparative study of the T-cell and B-cell phenotype

Lippman, S. M., Miller, T. P., Spier, C. M., Slymen, D. J. & Grogan, T. M., Jan 1 1988, In : Blood. 72, 2, p. 436-441 6 p.

Research output: Contribution to journalArticle

Open Access
113 Scopus citations